Leerink Partners initiated coverage on Palvella Therapeutics with a new price target

Nov 16, 2026
leerink-partners-initiated-coverage-on-palvella-therapeutics-with-a-new-price-target

Leerink Partners initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $228.00

Leave a comment